Parissa Tabrizian
Overview
Explore the profile of Parissa Tabrizian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
2290
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li P, Tabrizian P, Daher D, Gaviria F, Ajmera V, Montalvan-Sanchez E, et al.
Hepatology
. 2025 Mar;
PMID: 40067686
Background: The RETREAT score is a simple risk stratification tool for post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence that has been validated in retrospective cohort studies. A prospective, multicenter study...
2.
Moeckli B, Wassmer C, El Hajji S, Kumar R, Rodrigues Ribeiro J, Tabrizian P, et al.
Hepatology
. 2025 Mar;
PMID: 40042053
Background Aims: Immune checkpoint inhibitors (ICI) are increasingly used in patients with advanced hepatocellular carcinoma (HCC) patients awaiting liver transplantation (LT). However, concerns about the risk of post-transplant rejection persist....
3.
Tabrizian P, Marino R, Bhoori S, Zeitlhoefler M, Mehta N, Banz V, et al.
JHEP Rep
. 2025 Feb;
7(2):101246.
PMID: 39911942
Background & Aims: The combination of atezolizumab and bevacizumab offers a novel approach to immunomodulation, showing efficacy as a primary treatment in advanced hepatocellular carcinoma (HCC). Concerns about graft safety...
4.
Jo H, Yoon Y, Kim K, Tabrizian P, Marino R, Marin-Castro P, et al.
Int J Surg
. 2025 Feb;
PMID: 39907618
Background: In the current "sickest first" allocation policy for limited deceased liver grafts, identifying patients "too sick to transplant" before transplantation is crucial to optimize outcomes. This study aimed to...
5.
Xu E, Tabrizian P, Gutierrez J, Hoteit M, Ghaziani T, Zhou K, et al.
Hepatology
. 2025 Jan;
PMID: 39808828
Background And Aims: Patients with HCC meeting United Network for Organ Sharing (UNOS)-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS criteria ("All-Comers" [AC]) have...
6.
Tabrizian P, Marino R, Chow P
JHEP Rep
. 2025 Jan;
6(11):101181.
PMID: 39741696
Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape for advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab has demonstrated efficacy, establishing a new standard of care for...
7.
Tabrizian P, Pero A, Schwartz M
Clin Liver Dis
. 2024 Nov;
29(1):59-72.
PMID: 39608958
Hepatic resection has long been considered the preferred treatment for hepatocellular carcinoma (HCC) when feasible, but its role, as well as the outcomes is evolving rapidly. This article explores the...
8.
9.
Zhou K, Nguyen L, Tabrizian P, Mehta N
Liver Transpl
. 2024 Nov;
PMID: 39508738
No abstract available.
10.
Tabrizian P, Holzner M, Ajmera V, Kim A, Zhou K, Schnickel G, et al.
J Hepatol
. 2024 Sep;
82(3):512-522.
PMID: 39255928
Background & Aims: The use of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma (HCC) has become widespread with encouraging outcomes in the neoadjuvant setting. Safety and intention-to-treat...